Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Keytruda pembrolizumab Colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Classical Hodgkin lymphoma Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Renal cell carcinoma, adjuvant Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab recurrent, or metastatic cervical cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Nonsquamous NSCLC Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Gastrointestinal Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed